文献速递银屑病与炎症性皮肤病

S100A8/A9与富脂质坏死核心及银屑病患者生物制剂治疗的关联:观察性队列研究结果

Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study.
PubMed 文献 · J Invest Dermatol · 2022-06-21

该观察性队列研究在125例有冠状动脉CT血管造影的银屑病患者中分析S100蛋白与富脂质坏死核心(LRNC)的关系,发现S100A8/A9与LRNC独立相关(β=0.27,P=0.009)。73例患者中36例在1年时接受生物制剂治疗并有随访CT,其S100A8/A9水平降低79%、平均LRNC面积减少0.6 mm²。

要点

  • S100A8/A9与银屑病患者富脂质坏死核心独立相关(β=0.27,P=0.009)。
  • 生物制剂治疗1年时S100A8/A9水平降低79%(P=0.04)。
  • 生物制剂治疗1年时平均LRNC面积减少0.6 mm²(P=0.02)。

核心结论

  • 结果提示S100A8/A9可能在银屑病高危冠状动脉斑块形成中起作用。

研究设计与样本

  • 观察性队列研究,纳入125例有冠状动脉CT血管造影扫描及血清S100A7、S100A8、S100A9、S100A12、S100A8/A9水平可用的银屑病患者进行LRNC分析。
  • 73例患者中36例在1年时有冠状动脉CT血管造影扫描可用于分析。

主要发现

  • 在完全校正模型中,S100A8/A9与LRNC相关(β=0.27,P=0.009;n=125例银屑病患者)。
  • 1年时,接受生物制剂治疗的患者S100A8/A9水平降低79%(‒172[‒291.7至26.4] vs. ‒29.9[‒137.9至50.5];P=0.04)。
  • 1年时,接受生物制剂治疗的患者平均LRNC面积减少0.6 mm²(0.04[‒0.48至0.77] vs. ‒0.56[‒1.8至0.13];P=0.02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Psoriasis is a systemic inflammatory disease with an increased risk of atherosclerotic events and premature cardiovascular disease. S100A7, A8/A9, and A12 are protein complexes that are produced by activated neutrophils, monocytes, and keratinocytes in psoriasis. Lipid-rich necrotic core (LRNC) is a high-risk coronary plaque feature previously found to be associated with cardiovascular risk factors and psoriasis severity. LRNC can decrease with biologic therapy, but how this occurs remains unknown. We investigated the relationship between S100 proteins, LRNC, and biologic therapy in psoriasis. S100A8/A9 associated with LRNC in fully adjusted models (β = 0.27, P = 0.009; n = 125 patients with psoriasis with available coronary computed tomography angiography scans; LRNC analyses; and serum S100A7, S100A8, S100A9, S100A12, and S100A8/A9 levels). At 1 year, in patients receiving biologic therapy (36 of 73 patients had 1-year coronary computed tomography angiography scans available), a 79% reduction in S100A8/A9 levels (‒172 [‒291.7 to 26.4] vs. ‒29.9 [‒137.9 to 50.5]; P = 0.04) and a 0.6 mm2 reduction in average LRNC area (0.04 [‒0.48 to 0.77] vs. ‒0.56 [‒1.8 to 0.13]; P = 0.02) were noted. These results highlight the potential role of S100A8/A9 in the development of high-risk coronary plaque in psoriasis.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Berg AR, Hong CG, Svirydava M, et al. Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study. J Invest Dermatol. 2022. PMID: 35750149. doi:10.1016/j.jid.2022.05.1085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。